Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Severe Childhood Aggression (The TOSCA Study)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* DSM-IV diagnosis of ADHD, any subtype~* DSM-IV diagnosis of a disruptive behavior disorder, including CD or ODD~* Evidence of serious physical aggression, as rated on the Overt Aggression Scale-Modified, and as determined by parent or guardian ratings on the NCBRF D-Total Score. In addition, the blinded clinician must assign a clinical global impressions severity score of 4 or greater for aggression.~* Prior to random assignment, participants must be free of all psychotropic medicines for 2 weeks for most drugs (such as most antidepressants, alpha agonists, beta blockers, anxiolytics, mood stabilizers, and antihistamines), and 4 weeks for depot antipsychotics and fluoxetine.~Exclusion Criteria:~* Full-scale IQ below 71~* Pregnancy or a history of seizure disorder or other neurological or medical disorders for which medication may present a considerable risk~* Abnormal liver function~* Pervasive developmental disorder, schizophrenia or other psychotic disorders, or eating disorders~* Currently taking other psychotropic medications from which discontinuation would present a significant risk. Participants may not discontinue a satisfactory medication to participate.~* Presence or history of major depressive disorder~* Diagnosis of bipolar disorder~* A hypomanic/biphasic score of 36 or greater as rated by child's parent on the General Behavior Inventory and confirmed by clinician as indication of mood disorder~* Active substance abuse disorder or lack of control of substance use that does not allow for safe medication administration~* Evidence of current child abuse or neglect~* History of suicide attempt in the past year or current suicidal ideation with plan and/or intent~* Family history of type II diabetes in two or more first degree relatives, defined as biological parents and/or full biological siblings

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Children will receive active methylphenidate HCl and active risperidone. Parents will receive parent management training.
- 2 (Type: ACTIVE_COMPARATOR): Children will receive methylphenidate HCl and placebo instead of the active risperidone. Parents will receive parent management training.

Based on this trial design, predict the completion outcome and termination type (if applicable).